Wells Fargo raised the firm’s price target on RxSight to $61 from $45 and keeps an Overweight rating on the shares. The firm notes RxSight reported full Q4 results with revenue in line with its preannouncement, and lower gross margin/in-line OpEx. Sales, gross margin, and OpEx guidance for 2024 were reaffirmed.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on RXST:
- RxSight, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results
- RxSight price target raised to $61 from $43 at BTIG
- RxSight, Inc. to Report Fourth Quarter and Full Year 2023 Financial Results on February 28, 2024
- RxSight price target raised to $54 from $45 at Stifel
- RxSight price target raised to $41 from $35 at Needham
